Composite ICU, mechanical ventilation or death was reduced by telmisartan treatment at days 15 and 30. Death by day 30 was reduced in the telmisartan-treated group (control 22.54%, 16/71 telmisartan 4.29%, 3/70 participants p = 0.0023).

Kaplan-Meier analysis showed that telmisartan-treated patients had a lower median time-to-discharge (control=15 days telmisartan=9 days). Baseline absolute CRP serum levels were 5.53 ± 6.19 mg/dL (95% CI 6.91 to 4.15, n = 80) and 9.04 ± 7.69 (95% CI 9.04 to 10.82, n = 74) in the standard care and telmisartan added to standard care groups, respectively.

158 patients enrolled between May 14 and October 30 2020, were included in the analysis, 80 in the standard care and 78 in the telmisartan added to standard care group. 30th due to sharp reduction in recruitment.

The Lancet Regional Health – Western PacificĪ pragmatic decision to end the study before the third interim analysis was made on Oct.

The Lancet Regional Health – Southeast Asia.

The Lancet Gastroenterology & Hepatology.

Graphpad prism 5 disc ebay